Análisis Argos
LFST
LFSTSin veredicto
LifeStance Health Group, Inc. · Healthcare
US$ 11.27
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
44/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
✓Tiene más caja que deuda: balance fuerte.
Riesgos
!Venta significativa de insiders en el último trimestre.
!Balance frágil: la deuda pesa sobre el negocio.
VALOR2/6FUTURO5/6PASADO2/6SALUD2/6DIVIDENDO1/6
El Iris de calidad
VALOR2/6FUTURO5/6PASADO2/6SALUD2/6DIVIDENDO1/6
ValorCerca de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance razonable
DividendoEl dividendo aún duerme
Score Argos44de 100Sin veredicto
Ingresos▲14%
US$ 1.4 B
Margen operativo▼168%
1.7%
Flujo de caja libre▲22%
US$ 0.1 B
Deuda neta
US$ -0.1 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 4.4B
P/E452.3x
EV/EBITDA54.7x
FCF yield2.5%
ROIC1.3%
Margen operativo1.7%
Crecim. ingresos+13.9%/año
Piotroski F8/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 18 jun
LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com · 9 jun
4 Outpatient Home Health Stocks Benefiting From Industry Trends
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
zacks.com · 29 may
Wall Street Analysts Predict a 37.26% Upside in LifeStance Health (LFST): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com · 26 may
Bears are Losing Control Over LifeStance Health (LFST), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for LifeStance Health (LFST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
seekingalpha.com · 13 may
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
zacks.com · 13 may
Earnings Estimates Rising for LifeStance Health (LFST): Will It Gain?
LifeStance Health Group (LFST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com · 13 may
LifeStance Health Group (LFST) is a Great Momentum Stock: Should You Buy?
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com · 13 may
Wall Street Analysts See a 31.02% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
The consensus price target hints at a 31% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.